Alli-sponsored film gets "Rain Man" director

Share this article:
A GlaxoSmithKline-funded documentary on America's obesity epidemic will be directed by Barry Levinson, of Wag the Dog and Rain Man fame.

The Academy-Award winning director and the non-profit Creative Coalition will have complete editorial control over the film, GSK and the Creative Coalition reiterated in announcing Levinson's role at the Sundance Film Festival in Park City, Utah. GSK is sponsoring the film on behalf of its OTC weight loss brand Alli.

In a statement, Levinson said: "The evolution of the obesity crisis in America is a fascinating and compelling human story. It's the hidden enemy within our borders that no one talks about."

Earlier this month GSK launched new ads for Alli emphasizing unhealthy eating habits and bearing the tagline "Eat healthier, live happier." The new ads coincide with the release of a survey exploring “America's unhealthy relationship with food.” The survey found a disconnect between Americans' perceptions of their eating habits – 74% said they have a healthy relationship with food – and the fact that, by some estimates, two-thirds of Americans are overweight or obese.

Alli launched in 2007 with a $150 million ad campaign and took lumps from analysts as sales slumped in 2008. At launch, GSK projected the brand could reach $1.5 billion in sales. Third-quarter global sales were around $80 million.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...